-
Dutch drug regulator reports 10 cases of possible thrombosis after AstraZeneca jab

The Netherlands has seen 10 cases of noteworthy adverse side effects from AstraZeneca’s COVID-19 vaccine, a Dutch drug watchdog said on Monday, hours after the government put its vaccination program on hold following reports of possible unexpected side effects in other countries.
The Pharmacovigilance Centre Lareb said in a statement that 10 cases of reported side effects seen with the vaccine in the Netherlands included cases of possible thrombosis or embolisms, but none of the cases also included a lowered number of platelets, as has been reported reported in Denmark and Norway.
The Dutch government announced shortly before midnight on Sunday that it was halting use of the AstraZeneca vaccine. Its decision came hours before the Dutch began casting votes in a national election seen as a referendum on the government’s handling of the coronavirus pandemic.
The decision meant 43,000 vaccination appointments would be cancelled at short notice, the country’s health authorities said.
European vaccination programs have been upset in the last two weeks by reports that recipients of the AstraZeneca inoculation have suffered blood clots.
The European Medicines Agency has said there is no indication that the events were caused by the vaccination, a view that was echoed by the World Health Organization on Friday.
The Dutch vaccination program got off to a slow start, but hoped to catch up using the Pfizer-BioNtech, Moderna vaccines,and later the Johnson & Johnson vaccine. AstraZeneca, however, was to have accounted for 30 percent of 4.3 million vaccinations through April 15.
The Dutch health ministry said it hoped to resume vaccinations with AstraZeneca within several weeks, describing the halt as a “pause” taken only as a precaution.
“I hope (the halt will last) no longer than a couple of weeks, because we need vaccines to be able to put this nasty period behind us,” Health Minister Hugo de Jonge said on an early morning talk show.
The move follows a report that health workers in Norway who had recently received the vaccine were being treated in hospital for bleeding, blood clots and a low count of blood platelets.
The Netherlands has pre-ordered 12 million doses of AstraZeneca’s vaccine.
AstraZeneca said on Sunday a review of safety data of people vaccinated with its COVID-19 vaccine had shown no evidence of an increased risk of blood clots.
Denmark, Norway, Ireland, Iceland and Thailand have halted use of AstraZeneca’s vaccine over blood clotting concerns.
Italy’s northern region of Piedmont on Sunday said it would stop using a batch of AstraZeneca vaccines after a teacher died following his vaccination on Saturday, while Austria also stopped using a particular batch last week.
source: Reuters
Image source: Reuters
Levant
You May Also Like
Popular Posts
Caricature
BENEFIT AGM approves 10%...
- March 27, 2025
BENEFIT, the Kingdom’s innovator and leading company in Fintech and electronic financial transactions service, held its Annual General Meeting (AGM) at the company’s headquarters in the Seef District.
During the meeting, shareholders approved all items listed on the agenda, including the ratification of the minutes of the previous AGM held on 26 March 2024. The session reviewed and approved the Board’s Annual Report on the company’s activities and financial performance for the fiscal year ended 31 December 2024, and the shareholders expressed their satisfaction with the company’s operational and financial results during the reporting period.
The meeting also reviewed the Independent External Auditor’s Report on the company’s consolidated financial statements for the year ended 31 December 2024. Subsequently, the shareholders approved the audited financial statements for the fiscal year. Based on the Board’s recommendation, the shareholders approved the distribution of a cash dividend equivalent to 10% of the paid-up share capital.
Furthermore, the shareholders endorsed the allocation of a total amount of BD 172,500 as remuneration to the members of the Board for the year ended 31 December 2024, subject to prior clearance by related authorities.
The extension of the current composition of the Board was approved, which includes ten members and one CBB observer, for a further six-month term, expiring in September 2025, pending no objection from the CBB.
The meeting reviewed and approved the Corporate Governance Report for 2024, which affirmed the company’s full compliance with the corporate governance directives issued by the CBB and other applicable regulatory frameworks. The AGM absolved the Board Members of liability for any of their actions during the year ending on 31st December 2024, in accordance with the Commercial Companies Law.
In alignment with regulatory requirements, the session approved the reappointment of Ernst & Young (EY) as the company’s External Auditors for the fiscal year 2025, covering both the parent company and its subsidiaries—Sinnad and Bahrain FinTech Bay. The Board was authorised to determine the external auditors’ professional fees, subject to approval from the CBB, and the meeting concluded with a discussion of any additional issues as per Article (207) of the Commercial Companies Law.
Speaking on the company’s performance, Mr. Mohamed Al Bastaki, Chairman BENEFIT , stated: “In terms of the financial results for 2024, I am pleased to say that the year gone by has also been proved to be a success in delivering tangible results. Growth rate for 2024 was 19 per cent. Revenue for the year was BD 17 M (US$ 45.3 Million) and net profit was 2 Million ($ 5.3 Million).
Mr. Al Bastaki also announced that the Board had formally adopted a new three-year strategic roadmap to commence in 2025. The strategy encompasses a phased international expansion, optimisation of internal operations, enhanced revenue diversification, long-term sustainability initiatives, and the advancement of innovation and digital transformation initiatives across all service lines.
“I extend my sincere appreciation to the CBB for its continued support of BENEFIT and its pivotal role in fostering a stable and progressive regulatory environment for the Kingdom’s banking and financial sector—an environment that has significantly reinforced Bahrain’s standing as a leading financial hub in the region,” said Mr. Al Bastaki. “I would also like to thank our partner banks and valued customers for their trust, and our shareholders for their ongoing encouragement. The achievements of 2024 set a strong precedent, and I am confident they will serve as a foundation for yet another successful and impactful year ahead.”
Chief Executive of BENEFIT; Mr. Abdulwahed AlJanahi commented, “The year 2024 represented another pivotal chapter in BENEFIT ’s evolution. We achieved substantial progress in advancing our digital strategy across multiple sectors, while reinforcing our long-term commitment to the development of Bahrain’s financial services and payments landscape. Throughout the year, we remained firmly aligned with our objective of delivering measurable value to our shareholders, strategic partners, and customers. At the same time, we continued to play an active role in enabling Bahrain’s digital economy by introducing innovative solutions and service enhancements that directly address market needs and future opportunities.”
Mr. AlJanahi affirmed that BENEFIT has successfully developed a robust and well-integrated payment network that connects individuals and businesses across Bahrain, accelerating the adoption of emerging technologies in the banking and financial services sector and reinforcing Bahrain’s position as a growing fintech hub, and added, “Our achievements of the past year reflect a long-term vision to establish a resilient electronic payment infrastructure that supports the Kingdom’s digital economy. Key developments in 2024 included the implementation of central authentication for open banking via BENEFIT Pay”
Mr. AlJanahi concluded by thanking the Board for its strategic direction, the company’s staff for their continued dedication, and the Central Bank of Bahrain, member banks, and shareholders for their valuable partnership and confidence in the company’s long-term vision.
opinion
Report
ads
Newsletter
Subscribe to our mailing list to get the new updates!